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Idiopathic inflammatory myopathies (IIMs) may present as a primary autoimmune disorder, 
or overlap with other autoimmune/connective tissue diseases. The aetiology of IIM likely 
includes interactions between genetic and environmental factors. Several genetic variants 
common to multiple autoimmune disorders have been identified in recent genome-wide 
association studies (GWAS). A Myositis Genetics Consortium dermatomyositis (DM) 
GWAS also suggests genetic overlap with other autoimmune disorders.1 We sought to 
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extend these findings to identify novel genetic risk factors in a large cohort of adult/juvenile 
patients with DM and polymyositis (PM), by genotyping immune-related single nucleotide 
polymorphisms (SNPs) not captured through the DM GWAS.1
SNPs significantly associated (p<5×10−8) with 10 autoimmune disorders (systemic lupus 
erythematosus, rheumatoid arthritis, juvenile idiopathic arthritis, coeliac disease, Crohn’s 
disease, ulcerative colitis, psoriasis, type 1 diabetes, multiple sclerosis and systemic 
sclerosis) were identified from published GWAS or the National Human Genome Research 
Institute GWAS catalogue.2 Unique SNPs were identified (n=233), of which 99 had not 
been directly genotyped or captured (r2≥0.8 with genotyped SNPs) through our DM 
GWAS.1 These 99 SNPs were genotyped using Sequenom in 1001 European Caucasian 
individuals with definite/probable adult or juvenile DM or PM.34 Eighty-three SNPs passed 
quality control. GWAS data2 were imputed to the 1000G_phase 1 integrated_v3 reference 
panel using IMPUTE2.5 Concordance rates were >98% for 444/1001 cases overlapping the 
GWAS data set. INFO scores for the 83 SNPs were >0.6. The 1001 Sequenom cases were 
merged with 168 unique cases from the GWAS. Samples with >5% missing data were 
excluded, resulting in 1149 cases and 3572 controls (table 1). Association tests were 
performed for the 83 SNPs in DM and PM subgroups including juvenile cases, and the 
overall IIM group (SNPTEST V.2.4.1). Imputed genotype uncertainty was accounted for 
using the ‘score’ method. A random-effects meta-analysis of the individual country data sets 
was performed (META V.1.5). Local research ethics committee approval and informed 
consent were obtained.
Outside the major histocompatibility complex (MHC), a non-synonymous SNP rs2304256 
in TYK2 was identified reaching Bonferroni corrected significance in DM and the overall 
IIM group, but not in the PM subgroup (p=0.17) (table 2). TYK2 encodes a member of the 
Janus tyrosine kinase protein family, contributing to cytokine receptor signaling via its 
catalytic activity or kinase-independent scaffolding function, and may play a role in antiviral 
immunity. The associated SNP is predicted to be damaging to protein function using SIFT 
(Sorting Intolerant From Tolerant, a program that predicts whether an amino acid 
substitution affects protein function), but benign by Polyphen. rs2304256 is in the protein 
FERM (4.1 protein, ezrin, radixin, moesin) domain, which mediates interaction with Janus 
kinase and microtubule interacting protein 1, suggesting a possible increased interaction in 
DM cases. TYK2 has been associated with rheumatoid arthritis,6 juvenile idiopathic 
arthritis,7 systemic lupus erythematosus,8 type 1 diabetes9 and multiple sclerosis.10 Two 
SNPs 2335 bp 5′ of BLK (rs13277113) and within BLK (rs2618476) were associated with 
DM but not PM (table 2). These SNPs are highly correlated (r2>0.95, HapMap CEU) with 
rs2736340, 7.5 kb 5′ of BLK, supporting the previous DM GWAS results,1 and suggesting a 
role of B cells in development of DM. No non-MHC SNPs were associated with PM at a 
Bonferroni corrected significance level.
We have identified TYK2 as a novel associated locus for DM. This study confirms TYK2 as 
an autoimmune gene and suggests a genetic overlap of DM with other autoimmune 
disorders, indicating genetic heterogeneity between PM and DM, although the difference 
may be due to the smaller PM sample size. These results require replication in an 
independent cohort and functional studies of the pathogenic role of TYK2 in myositis. Our 
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analysis supports the study of additional immune-related loci in larger cohorts, using SNP 
arrays such as the Immunochip.
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Table 1
Polymyositis, dermatomyositis and matched control sample numbers included in the final analysis
Country
DM cases PM cases
Cases total Controls totalJDM DM DM total JPM PM PM total
1. Czech Republic 11 134 145 – 61 61 206 166
2. Hungary 14 71 85 2 79 81 166 90
3. Netherlands/Sweden 4 54 58 – 67 67 125 642
4. Spain 4 61 65 – – – 65 259
5. UK 183 203 386 6 195 201 587 2415
TOTAL 216 523 739 8 402 410 1149 3572
DM, dermatomyositis; JDM, juvenile dermatomyositis; JPM, juvenile polymyositis; PM, polymyositis.
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